IMP3 and serous adenocarcinoma: Zheng et al. found IMP3 positivity in more than 50% of tumor cells in 94% of serous carcinomas and 49% of clear cell carcinomas compared to 3% of endometrioid carcinomas and complete negativity in 8 mucinous endometrial carcinomas [19].